文献速递浆细胞疾病

新型BCMA PBD-ADC联合ATM/ATR/WEE1抑制剂或硼替佐米在多发性骨髓瘤中诱导协同致死

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma.
PubMed 文献 · Leukemia · 2020-02-14

该研究探讨新型BCMA抗体药物偶联物MEDI2228(携带PBD二聚体tesirine)在多发性骨髓瘤中的杀伤机制。MEDI2228通过激活ATM/ATR等DNA损伤反应通路诱导细胞凋亡,并与ATM/ATR/WEE1抑制剂或硼替佐米协同杀伤耐药骨髓瘤细胞,在体内显著延长生存。

要点

  • MEDI2228通过激活ATM/ATR/CHK1/2等DNA损伤反应通路诱导骨髓瘤细胞凋亡。
  • MEDI2228与ATM/ATR/WEE1抑制剂或硼替佐米协同诱导耐药骨髓瘤细胞死亡。
  • 联合方案在体内增加核γH2AX焦点、不可逆DNA损伤并延长宿主生存。

核心结论

  • MEDI2228与DDR抑制剂或硼替佐米联合是新型组合策略,支持其在复发难治多发性骨髓瘤中的临床开发。

研究设计与样本

  • 研究采用新型BCMA抗体药物偶联物MEDI2228,在骨髓瘤细胞及体内模型中评估其单独及联合ATM/ATR/WEE1抑制剂或硼替佐米的杀伤效果。

主要发现

  • MEDI2228较其抗微管MMAF-ADC同源物更有效诱导骨髓瘤细胞毒性,且不受耐药性、BCMA水平、p53状态及骨髓基质细胞和IL-6保护的影响。
  • MEDI2228在凋亡前激活ATM/ATR激酶、CHK1/2、CDK1/2和H2AX磷酸化,并伴随DDR相关基因表达。
  • MEDI2228与靶向ATM/ATR/WEE1检查点的DDR抑制剂协同诱导骨髓瘤细胞致死。
  • 亚优剂量MEDI2228与硼替佐米协同触发耐药骨髓瘤细胞凋亡,部分通过调节RAD51和累积受损DNA实现。
  • 联合方案在体内通过增加核γH2AX表达焦点、不可逆DNA损伤和肿瘤细胞死亡,较单药诱导更优疗效并显著延长宿主生存。

临床怎么用

  • 对于复发难治多发性骨髓瘤,可考虑MEDI2228联合ATM/ATR/WEE1抑制剂或硼替佐米的组合策略,但需进一步临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To target mechanisms critical for multiple myeloma (MM) plasma cell adaptations to genomic instabilities and further sustain MM cell killing, we here specifically trigger DNA damage response (DDR) in MM cells by a novel BCMA antibody-drug conjugate (ADC) delivering the DNA cross-linking PBD dimer tesirine, MEDI2228. MEDI2228, more effectively than its anti-tubulin MMAF-ADC homolog, induces cytotoxicity against MM cells regardless of drug resistance, BCMA levels, p53 status, and the protection conferred by bone marrow stromal cells and IL-6. Distinctly, prior to apoptosis, MEDI2228 activates DDRs in MM cells via phosphorylation of ATM/ATR kinases, CHK1/2, CDK1/2, and H2AX, associated with expression of DDR-related genes. Significantly, MEDI2228 synergizes with DDR inhibitors (DDRi s) targeting ATM/ATR/WEE1 checkpoints to induce MM cell lethality. Moreover, suboptimal doses of MEDI2228 and bortezomib (btz) synergistically trigger apoptosis of even drug-resistant MM cells partly via modulation of RAD51 and accumulation of impaired DNA. Such combination further induces superior in vivo efficacy than monotherapy via increased nuclear γH2AX-expressing foci, irreversible DNA damages, and tumor cell death, leading to significantly prolonged host survival. These results indicate leveraging MEDI2228 with DDRi s or btz as novel combination strategies, further supporting ongoing clinical development of MEDI2228 in patients with relapsed and refractory MM.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Xing L, Lin L, Yu T, et al. A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020. PMID: 32060401. doi:10.1038/s41375-020-0745-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。